Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for CTCL
Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Previously, BNZ-1 was given orphan drug designation by the US Food and Drug Administration (FDA). Recently, Bioniz Therapeutics wrapped up a phase 2 study of BNZ-1 in […]